Photodynamic therapy (PDT) is an effective treatment method for tumors. But the specifically accumulated of photosensitizer was very difficult in the tumor site, which greatly limited the efficacy of PDT. Here, mitochondria-targeted Janus mesoporous nanoplatform (JPMO-Pt-CTPP-ZnPc) for PDT was prepared, the nanoplatform has uniform size (275 nm) and good dispersion and biocompatibility. The confocal laser scanning microscopy (CLSM) revealed the signal of ZnPc of JPMO-Pt-CTPP-ZnPc were higher than JPMO-Pt-ZnPc in tumor cells, and flow cytometry results showed the cell uptake efficiency of JPMO-Pt-CTPP-ZnPc was 2.5-fold higher than that of JPMO-Pt-ZnPc. This revealed the modification of CTPP significantly improves the targeting ability of the nanoplatform. In vitro anti-tumor experiment showed the JPMO-Pt-CTPP-ZnPc significantly inhibited the growth of tumor cells upon the irradiation of low-power laser, and the survival rate of cells incubated with 60 μg/mL JPMO-Pt-CTPP-ZnPc was only 3%. Simultaneously, compared with JPMO-Pt-ZnPc (not modified with mitochondria targeting molecules CTPP), the PDT efficacy of JPMO-Pt-CTPP-ZnPc was significantly better, as it has targeted mitochondria in cells.

光动力疗法（PDT）是治疗肿瘤的有效方法。但光敏剂在肿瘤部位的特异性积累非常困难，这极大地限制了PDT的疗效。本研究制备了用于PDT的靶向线粒体的Janus介孔纳米平台（JPMO-Pt-CTPP-ZnPc），该纳米平台尺寸均匀（275 nm），具有良好的分散性和生物相容性。共聚焦激光扫描显微镜（CLSM）显示JPMO-Pt-CTPP-ZnPc在肿瘤细胞中的ZnPc信号高于JPMO-Pt-ZnPc，流式细胞术结果显示JPMO-Pt-CTPP-ZnPc的细胞摄取效率比 JPMO-Pt-ZnPc 高 2.5 倍。这表明 CTPP 的修饰显着提高了纳米平台的靶向能力。体外抗肿瘤实验表明，JPMO-Pt-CTPP-ZnPc在低功率激光照射下显着抑制肿瘤细胞的生长，60 μg/mL JPMO-Pt-CTPP-ZnPc孵育的细胞存活率仅为3%。同时，与JPMO-Pt-ZnPc（未用线粒体靶向分子CTPP修饰）相比，JPMO-Pt-CTPP-ZnPc的PDT疗效明显更好，因为它靶向细胞内的线粒体。